Literature DB >> 23331540

Bronchoscopy as an indicator of tracheobronchial fungal infection in non-neutropenic intensive-care unit patients.

O Yazıcıoğlu Moçin1, Z Karakurt, F Aksoy, G Güngör, M Partal, N Adıgüzel, E Acartürk, S Batı Kutlu, R Baran, H Erdem.   

Abstract

We aimed to establish that a bronchoscopic view can be as reliable as microbiology, and support an empirical tracheobronchial fungal infection (TBFI) treatment decision. We retrospectively studied 95 respiratory failure patients with suspected TBFI admitted to the intensive-care unit (ICU) in 2008 with sticky secretions, hyperaemic mucosa, and whitish plaques on bronchoscopic view. Patients not suspected of having TBFI were chosen as a control group (n = 151). Broncheoalveolar lavage (BAL) fluid was cultured, and biopsy samples were taken from the lesions. Biopsy samples positive for fungi were defined as 'proven', only BAL-positive (+ fungi) cases were 'probable TBFI', and BAL-negative (- fungi) cases were 'possible TBFI'. BAL (+ fungi) and BAL (- fungi) in the control group were defined as 'colonization' and 'no TBFI', respectively. The sensitivity, specificity and positive and negative predictive values of BAL (+ fungi) were 85.1% (63/74), 81.4% (140/172), 66.3% (63/95), and 92.7% (140/151), respectively. Biopsies were performed in 78 of 95 patients, and 28 were proven TBFI with fungal elements, and 100% were BAL (+ fungi). Probable TBFI was seen in 30 of 95 patients with BAL (+ fungi), and possible TBFI (BAL(- fungi)) in 25 of 95. Among the 95 patients, microbiology revealed fungi (90.5% Candida species; 9.5% Aspergillus) in 63 (66.3%). In the controls, the colonization and no TBFI rates were 11 of 151 and 140 of 151, respectively. Observing sticky secretions, hyperaemic mucosa and whitish plaques by bronchoscopy is faster than and may be as reliable as microbiology for diagnosing TBFI. These findings are relevant for empirical antifungal therapy in suspected TBFI patients in the ICU.
© 2012 The Authors Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23331540     DOI: 10.1111/1469-0691.12112

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  4 in total

1.  Fungal "colonisation" is associated with increased mortality in medical intensive care unit patients with liver cirrhosis.

Authors:  Tobias Lahmer; Marlena Messer; Ulrich Mayr; Bernd Saugel; Sebastian Noe; Caroline Schultheiss; Philipp Thies; Christoph Spinner; Simon Nennstiel; Christiane Schwerdtfeger; Veit Phillip; Roland M Schmid; Wolfgang Huber
Journal:  Mycopathologia       Date:  2014-10-28       Impact factor: 2.574

Review 2.  Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.

Authors:  Valliappan Muthu; Ritesh Agarwal; Atul Patel; Soundappan Kathirvel; Ooriapadickal Cherian Abraham; Ashutosh Nath Aggarwal; Amanjit Bal; Ashu Seith Bhalla; Prashant N Chhajed; Dhruva Chaudhry; Mandeep Garg; Randeep Guleria; Ram Gopal Krishnan; Arvind Kumar; Uma Maheshwari; Ravindra Mehta; Anant Mohan; Alok Nath; Dharmesh Patel; Shivaprakash Mandya Rudramurthy; Puneet Saxena; Nandini Sethuraman; Tanu Singhal; Rajeev Soman; Balamugesh Thangakunam; George M Varghese; Arunaloke Chakrabarti
Journal:  Lancet Infect Dis       Date:  2022-04-04       Impact factor: 71.421

3.  Subglottic mucormycosis in a COVID-19 patient: a rare case report.

Authors:  Behrooz Amirzargar; Mehrdad Jafari; Zahra Ahmadinejad; Mohammadreza Salehi; Sina Chalabi; Pouyan Aminishakib; Faeze Salahshoor; Sadegh Khodavaisy; Mohammadsadegh Zabihidan
Journal:  Oxf Med Case Reports       Date:  2022-07-26

4.  Pseudomembranous Invasive Tracheobronchial Aspergillosis with Fulminant Hepatitis and Hemophagocytic Syndrome.

Authors:  Suguru Majima; Shotaro Okachi; Motoyo Asano; Keiko Wakahara; Naozumi Hashimoto; Mitsuo Sato; Masatoshi Ishigami; Yoshinori Hasegawa
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.